Guidant’s $3 Bil. Cook Purchase Hinges On Ownership Of Subsidiary, Data
This article was originally published in The Gray Sheet
Executive Summary
Guidant's $3 bil. purchase of Cook Group does not represent a "change of ownership" under the terms of a 1997 licensing agreement between subsidiary Cook, Inc., Angiotech Pharmaceuticals and Boston Scientific, Guidant asserts
You may also be interested in...
Guidant Shuffles Capek, Boosts Delivery Options With X-Technologies Buy
Guidant is turning to a polished communications, organizational and policy executive to oversee its vascular intervention business with the elevation of company veteran Dana Mead
Guidant Shuffles Capek, Boosts Delivery Options With X-Technologies Buy
Guidant is turning to a polished communications, organizational and policy executive to oversee its vascular intervention business with the elevation of company veteran Dana Mead
Guidant Considers Alternatives As Court Enjoins Paclitaxel DELIVER Data
Guidant is exploring a supply arrangement that would be consistent with Cook, Inc.'s original licensing agreement with Angiotech Pharmaceuticals in moving forward with a paclitaxel-eluting stent platform